Meet our new member: IOV (Veneto Oncology Institute) – Interview with Prof. Antonio Rosato
As part of our commitment to fostering strong regional health collaboration, we are delighted to welcome IOV – Veneto Oncology Institute as a new associate member of EUREGHA!
In a special welcome interview, we had the pleasure of speaking with Prof. Antonio Rosato, Scientific Director of Istituto Oncologico Veneto IRCCS; to explore his vision, expertise, and how IOV will contribute to our network. You can find the full interview below!
EUREGHA continues to grow, and we look forward to introducing more new members to our expanding community in the coming months. Stay tuned for more updates!
Could you briefly introduce IOV to a European audience maybe unfamiliar with the Italian healthcare system?
The Veneto Oncology Institute IRCCS is a national center of excellence in oncology (Comprehensive Cancer Center) located in northern Italy and recognized by the Ministry of Health as an IRCCS (Scientific Institute for Research, Hospitalization, and Healthcare. The institute operates within the Veneto regional healthcare system. Accredited by the OECI, the IOV is dedicated to the entire spectrum of oncological pathology, from prevention and screening to advanced treatments and palliative care. Our mission is to integrate multidisciplinary clinical excellence in oncology with high-impact translational research, ensuring that scientific innovation is rapidly transformed into personalized therapies for patients.
What motivated IOV to join the EUREGHA network, and what are your main expectations from engaging with a European network of regional health actors?
Joining EUREGHA is a strategic choice for IOV to align regional oncological excellence with the European Plan Against Cancer, ensuring our patients have access to cutting-edge integrated care. Through constant dialogue with key European partners, we aim to refine our clinical models and accelerate the adoption of innovative therapeutic pathways. This participation will also strengthen our ability to build international partnerships for high-impact research projects (Horizon Europe and EU4Health), consolidating the IOV’s role in the European Union’s healthcare policy landscape.
As a specialised oncology institute, what are IOV’s key priorities in cancer care, research, or system organisation for the coming years?
Our priorities for the coming years focus on three pillars: advancing precision medicine through clinical genomics, strengthening translational research to accelerate the “from bench to bedside” process (especially in immunotherapy), and enhancing digital governance within the Veneto Oncology Network to ensure uniform access to innovation throughout the region.
How do you see IOV engaging with EUREGHA’s thematic activities and exchanges, such as the working groups, in the coming period?
IOV intends to actively participate in EUREGHA working groups through the multidisciplinary involvement of its researchers. Our commitment will focus strategically on the fields of Cancer , with a specific interest also in the field of digital health. In these areas, we will share the best practices of the IOV model and the results of our translational research, with the dual objective of consolidating the achievements made and promoting continuous improvement in treatment methods. We aim to play a proactive role in European planning, making our Grant Office available to build solid consortia and develop joint pilot projects. The goal is to transform the exchange of knowledge into concrete clinical and organizational solutions, strengthening the link between European health policies and the regional oncology reality.
Looking ahead to the next 12 months what does IOV hope to bring to the EUREGHA network, and what do you hope to gain?
Our goal is to bring to the EUREGHA network the practical experience of the IOV in coordinating the Veneto Oncology Network and our established model of patient-centered translational research. At the same time, we are eager to engage with European partners on digital health tools, integrated cancer care models, and policy innovations that can accelerate our transformation toward precision oncology. We firmly believe that this collaboration represents an invaluable growth opportunity for both parties.
SHARE THE POST
related posts
